DekaBank Deutsche Girozentrale’s Intra-Cellular Therapies Inc. ITCI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-51,997
| Closed | -$4.09M | – | 1393 |
|
|
2025
Q2 | $4.09M | Hold |
51,997
| – | – | 0.01% | 607 |
|
|
2025
Q1 | $6.74M | Hold |
51,997
| – | – | 0.01% | 510 |
|
|
2024
Q4 | $4.32M | Hold |
51,997
| – | – | 0.01% | 600 |
|
|
2024
Q3 | $3.8M | Sell |
51,997
-502
| -1% | -$37.7K | 0.01% | 641 |
|
|
2024
Q2 | $3.71M | Buy |
52,499
+502
| +1% | +$34.8K | 0.01% | 637 |
|
|
2024
Q1 | $3.59M | Hold |
51,997
| – | – | 0.01% | 652 |
|
|
2023
Q4 | $3.79M | Buy |
51,997
+11,000
| +27% | +$633K | 0.01% | 640 |
|
|
2023
Q3 | $2.19M | Buy |
40,997
+997
| +2% | +$58.1K | 0.01% | 716 |
|
|
2023
Q2 | $2.46M | Buy |
40,000
+5,000
| +14% | +$312K | 0.01% | 706 |
|
|
2023
Q1 | $1.93M | Hold |
35,000
| – | – | ﹤0.01% | 730 |
|
|
2022
Q4 | $1.85M | Sell |
35,000
-8,219
| -19% | -$412K | ﹤0.01% | 734 |
|
|
2022
Q3 | $1.93M | Sell |
43,219
-364
| -0.8% | -$19K | 0.01% | 714 |
|
|
2022
Q2 | $2.48M | Sell |
43,583
-917
| -2% | -$52K | 0.01% | 679 |
|
|
2022
Q1 | $2.72M | Buy |
44,500
+12,700
| +40% | +$660K | 0.01% | 689 |
|
|
2021
Q4 | $1.63M | Buy |
31,800
+900
| +3% | +$37.8K | ﹤0.01% | 820 |
|
|
2021
Q3 | $1.09M | Hold |
30,900
| – | – | ﹤0.01% | 880 |
|
|
2021
Q2 | $1.21M | Hold |
30,900
| – | – | ﹤0.01% | 867 |
|
|
2021
Q1 | $993K | Hold |
30,900
| – | – | ﹤0.01% | 904 |
|
|
2020
Q4 | $953K | Sell |
30,900
-1,500
| -5% | -$39.4K | ﹤0.01% | 881 |
|
|
2020
Q3 | $811K | Buy |
+32,400
| New | +$739K | ﹤0.01% | 827 |
|
|
2019
Q4 | – | Sell |
-65,700
| Closed | -$493K | – | 1233 |
|
|
2019
Q3 | $493K | Sell |
65,700
-65,700
| -50% | -$630K | ﹤0.01% | 774 |
|
|
2019
Q2 | $1.67M | Buy |
131,400
+42,500
| +48% | +$545K | 0.01% | 667 |
|
|
2019
Q1 | $1.95M | Buy |
88,900
+9,200
| +12% | +$118K | 0.01% | 615 |
|
|
2018
Q4 | $868K | Sell |
79,700
-9,200
| -10% | -$149K | 0.01% | 716 |
|
|
2018
Q3 | $1.95M | Buy |
88,900
+12,700
| +17% | +$266K | 0.01% | 628 |
|
|
2018
Q2 | $1.35M | Sell |
76,200
-137,000
| -64% | -$2.78M | 0.01% | 681 |
|
|
2018
Q1 | $4.39M | Sell |
213,200
-76,000
| -26% | -$1.48M | 0.03% | 418 |
|
|
2017
Q4 | $3.35M | Hold |
289,200
| – | – | 0.03% | 454 |
|
|
2017
Q3 | $3.35M | Hold |
289,200
| – | – | 0.03% | 459 |
|
|
2017
Q2 | $3.67M | Buy |
289,200
+50,000
| +21% | +$580K | 0.03% | 437 |
|
|
2017
Q1 | $3.89M | Buy |
239,200
+229,200
| +2,292% | +$3.32M | 0.04% | 386 |
|
|
2016
Q4 | $155K | Buy |
+10,000
| New | +$141K | ﹤0.01% | 863 |
|
|
2016
Q3 | – | Sell |
-76,000
| Closed | -$2.85M | – | 1034 |
|
|
2016
Q2 | $2.85M | Buy |
+76,000
| New | +$2.73M | 0.03% | 404 |
|
Other funds holding ITCI
DekaBank Deutsche Girozentrale's ITCI Position: Q3 2025 in Review
DekaBank Deutsche Girozentrale sold out of Intra-Cellular Therapies Inc. (ITCI) in Q3 2025, closing a stake of 51,997 shares — an estimated $4.09M sold.
DekaBank Deutsche Girozentrale first reported a position in ITCI in Q2 2016 and held it in 33 quarters. The position peaked at $6.74M in Q1 2025. 1 fund tracked by Wall St. Rank holds ITCI as of Q3 2025.
- DekaBank Deutsche Girozentrale reported no remaining Intra-Cellular Therapies Inc. position as of Q3 2025 after selling out during the quarter.
- DekaBank Deutsche Girozentrale sold 51,997 Intra-Cellular Therapies Inc. shares in Q3 2025, an estimated $4.09M.
- DekaBank Deutsche Girozentrale first reported a position in Intra-Cellular Therapies Inc. in Q2 2016 and held it in 33 quarters.
- DekaBank Deutsche Girozentrale's Intra-Cellular Therapies Inc. position peaked at $6.74M in Q1 2025.
- 1 fund tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2025.
Based on DekaBank Deutsche Girozentrale's 13F filing for Q3 2025, filed 3 Nov 2025.